

INTERNATIONAL CANCER RESEARCH PARTNERSHIP

England & Wales · Charity number 1204566

Details

Status Registered

Legal form CIO

Registered 2023-09-04

Register [View on the Charity Commission register](#)

Contact

Address International House
10 Churchill Way
Cardiff
CF10 2HE

Phone 07889599948

Email operations@icrpartnership.org

Website <https://www.icrpartnership.org/>

Activities

Objects: TO PROMOTE AND PROTECT THE GOOD HEALTH OF PEOPLE AFFECTED BY CANCER AND THE PUBLIC BY PROMOTING COLLABORATION BETWEEN CANCER RESEARCH FUNDERS ACROSS THE WORLD AND BY CO-ORDINATING RESEARCH INTO THE CAUSES, PREVENTION, TREATMENT AND CURE OF ALL FORMS OF CANCER, TO MAXIMISE THE VALUE AND BENEFITS OF CANCER RESEARCH.

Activities: Provision of a public database of global cancer research projects. Enhance communication between cancer research funders to promote collaboration. Publish regular reports on global cancer research activity.

Classification

- **How:** Provides Services, Acts As An Umbrella Or Resource Body
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** Other Charities Or Voluntary Bodies, Other Defined Groups, The General Public/mankind

Geography

- Australia
- Belgium
- Canada
- France
- Ireland
- Italy
- Japan
- Netherlands
- South Africa
- Spain
- United States
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£17,936	£32,721	-	-
2024-03-31	£71,751	£23,274	-	-

Trustees

Name	Role	Appointed
Dr Katherine McKenzie PhD		
Dr Lynn Turner		2022-07-29
Kimberly Badovinac MA, MBA		2022-09-08
Richard Kirk Stephens		2023-03-28
Sarah Chalmers		2023-12-29

INTERNATIONAL CANCER RESEARCH PARTNERSHIP

England & Wales - Charity number 1204566

Accounts

International Cancer Research Partnership (ICRP) Annual Report FINAL

- **Charity name:** International Cancer Research Partnership
- **Charity registration number:** 1204566
- **Report covering the period:** 1 April 2024 – 31 March 2025

Objectives and Activities

Summary of the purposes of the charity as set out in its governing document¹
To promote and protect the good health of people affected by cancer and the public by promoting collaboration between cancer research funders across the world and by co-ordinating research into the causes, prevention, treatment and cure of all forms of cancer, to maximise the value and benefits of cancer research.
Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts²
<ol style="list-style-type: none">1. Provision of a public database of global cancer research projects - classified by research and cancer type - that are funded by the partner organisations, to enable cancer researchers and funders to identify opportunities for collaboration, avoid duplication, and highlight gap areas where further investment is required to enhance research for the benefit of cancer patients and the public.2. Enhancing communication between cancer research funders to promote collaboration, share knowledge and maximise resources by avoiding duplicative activities. This is achieved through monthly online meetings for partners, an annual meeting, and provision of resources through the partner website and forum.3. Publish regular reports on global cancer research activity, to highlight opportunities to enhance research, for the benefit of partners, patients, policymakers and the wider public.
Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit³
The trustees have complied with their duty to have due regard to the commission's public benefit guidance

Achievements and Performance

Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole⁴

¹ SORP reference Para 1.17

² SORP reference Para 1.17 and 1.19

³ SORP reference Para 1.18

⁴ SORP reference Para 1.20

1. **Enhancing the database of cancer research**

In 2024-25, 54,438 new projects were uploaded to the database (an increase from 7701 in 2023-24) and updates processed for 306 projects. Essential maintenance was conducted for the website and database, and further enhancements were also made to the database search on the website to improve the user experience.

2. **Co-funding between partners**

To address identified gaps in cancer research, many of ICRP's members co-funded projects with other funders. Examples included CRUK & NCI (US); AECC (Spain) & WCR (Scotland); AECC (Spain), CRUK, AIRC (Italy); MRA (US) & RTFCCR (Switzerland).

3. **Publications, evaluations and analysis**

a. **Metastatic Breast Cancer:** an ICRP sub-group continued working with the Metastatic Breast Cancer Alliance (MBCA), to analyse investment in metastatic breast cancer (MBC) research from 2014-2020. The report had already identified that previously (2000-2013), 7% of the \$15 billion in breast cancer research dollars globally was for MBC. In 2014-2020, 13% of all breast cancer research dollars was devoted to MBC and investment in treatment resistance had increased (see [summary](#)). Patient advocates identified five new priority areas to examine (research into: Survivorship, Pregnancy, Microenvironment, Brain & leptomeningeal disease, Treatment - rare sub-types) with the aim of producing a report for the MBCA partners' meeting in Spring 2026.

b. **ICRP reports:** essential preparatory work was done to underpin future analyses on childhood cancer, survivorship and global landscape analyses.

c. **Gender & PI:** an international sub-group of partner representatives in support of the [Lancet Commission on Women, power and cancer](#) analysed the gender of principal investigators in ICRP projects, in preparation for a publication later in 2025/early 2026.

4. **Membership and communications**

Newsletters were published via the website and distributed by email to potential new partners. Funding opportunities from partner organisations were highlighted on the [ICRP website](#) and by Twitter/X to attract global applicants. Discussions were ongoing with the European Commission on including funded projects that had been coded to research and cancer type as part of the Lancet Commission roadmap for cancer research in Europe in 2022 in the ICRP database. New potential partners were identified during the course of the year.

5. **Patient engagement**

Patient advocates led the identification of priority questions in the Metastatic Breast Cancer Analysis, and presented a panel at the May 2024 partner meeting.

6. **Annual and virtual meetings**

A hybrid in-person/remote partner meeting was held in Toronto in May 2024, on the theme "Doing More Together". Over 130 participants attended from 12 countries. Open sessions held on May 14th and 15th focused on Global Oncology - Challenging the Status Quo through Collaboration, Cancer Clinical Trials, AI in Cancer Research, Innovative cancer research funding models, Research Impact, Patient Engagement and Identifying and Funding Game-Changing Research. The

[meeting report](#) was published in June 2024 and a list of priority areas was produced to follow up during the year. Five virtual partner meetings were held with presentations from partners on topics of interest or collaborative funding opportunities.

7. **Organisation, finance & operations**

The process of migrating financial functions to a UK bank continued and the Charities Aid Foundation Bank (CAF Bank) was identified as the preferred option [Post AGM Note: Completed in August 2025]

Financial Review

Review of the charity's financial position at the end of the period	Para 1.21	See Fiscal Statement (Appendix)
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	6 month operational reserve for winding up operations
Amount of reserves held	Para 1.22	£80K (\$100K USD)
Reasons for holding zero reserves	Para 1.22	n/a
Details of fund materially in deficit	Para 1.24	n/a
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	n/a

Additional information (optional)

The charity's principal sources of funds (including any fundraising) SORP Para 1.47	Membership dues
--	-----------------

Structure, Governance and Management

Description of charity's trusts:		
Type of governing document	Para 1.25	Association Model Constitution
How is the charity constituted?	Para 1.25	Charitable Incorporated Organisation
Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees	Para 1.25	Skills audit

Reference and Administrative details



Charity name	International Cancer Research Partnership
Other name the charity uses	n/a
Registered charity number	1204566
Charity's principal address	International House, 10 Churchill Way, Cardiff, CF10 2HE, UK

Names of the charity trustees who manage the charity

Trustee Name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
Iain Frame		Resigned Sep 2024	
Kimberly Badovinac			
Katherine McKenzie			
Lynn Turner			
Richard Stephens			
Sarah McDonald			


Declarations

The trustees declare that they have approved the trustees' report above.
Signed on behalf of the charity's trustees

Signature(s)		
Full name(s)	Lynn Turner	Sarah McDonald
Position (e.g. Trustee, Secretary, Chair etc.)	Trustee	Trustee
Date	23/01/26	23/01/2026

International Cancer Research Partners (ICRP)
FINANCIAL REPORT for the period of April 1, 2024 - March 31, 2025



Chair, Finance Committee Kimberly Badovinac	Sponsor ICRP	As at March 31, 2025
Host Institution Canadian Partnership against Cancer		
SOURCES OF FUNDS	USD	USD(\$)
Balance of funds as of April 1, 2024	\$ 202,459.90	
Membership Fees for FY23/24 received in FY24/25 (Note 2)	8,000.00	
Membership Fees for FY24/25	25,000.00	
Total funds available for April 1, 2024 - March 31, 2025	A	\$ 235,459.90
EXPENDITURES INCURRED		
1) Salary and Benefits		
a) Consulting Fee	\$ 45,098.53	
	Subtotal	\$ 45,098.53
2) Operations		
a) ICRP webex & other subscriptions etc.	\$ 2,364.21	
b) Travel & Meeting expenses	12,745.10	
	Subtotal	\$ 15,109.31
Total expenditures incurred April 1, 2024 - March 31, 2025	B	\$ 60,207.84
UNSPENT BALANCE	A-B	\$ 175,252.06
TOTAL BALANCE USD		\$ 175,252.06
Unrealized foreign exchange losses (Note 1)		\$ (88,219.89)
Total Adjusted Balance USD		\$ 87,032.17
SIGNATURE		
<p>Note 1: As at March 31, 2025, the USD equivalent of the \$125,118.13 CAD balance in CPAC's account is \$87,032.17 USD using an exchange rate of 0.6956. This difference is due to the effect of accumulated currency fluctuation since August 1, 2013, the unrealized foreign exchange losses are \$88,219.89 USD.</p> <p>Note 2: FY23/24 membership fee of USD 8,000 from Japan Agency for Medical Research and Development was received on April 4, 2024 and was reflected in FY24/25 statement.</p>		
<p>I hereby certify that the funds received and the expenditures incurred were transacted wholly on behalf of the grantee, and that the supporting documents are available for monitoring purposes.</p> 		
<p>Jessie Yin, CPA, CGA Controller, Finance & Administration Canadian Partnership against Cancer May 9, 2025 Date</p>		

INTERNATIONAL CANCER RESEARCH PARTNERSHIP

England & Wales - Charity number 1204566

Accounts

International Cancer Research Partnership (ICRP) Annual Report

- **Charity name:** International Cancer Research Partnership
- **Charity registration number:** 1204566
- **Report covering the period:** 4 September 2023 – 31 March 2024¹

Objectives and Activities

Summary of the purposes of the charity as set out in its governing document²
To promote and protect the good health of people affected by cancer and the public by promoting collaboration between cancer research funders across the world and by co-ordinating research into the causes, prevention, treatment and cure of all forms of cancer, to maximise the value and benefits of cancer research.
Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts³
<ol style="list-style-type: none">1. Provision of a public database of global cancer research projects - classified by research and cancer type - that are funded by the partner organisations, to enable cancer researchers and funders to identify opportunities for collaboration, avoid duplication, and highlight gap areas where further investment is required to enhance research for the benefit of cancer patients and the public.2. Enhancing communication between cancer research funders to promote collaboration, share knowledge and maximise resources by avoiding duplicative activities. This is achieved through monthly online meetings for partners, an annual meeting, and provision of resources through the partner website and forum.3. Publish regular reports on global cancer research activity, to highlight opportunities to enhance research, for the benefit of partners, patients, policymakers and the wider public.
Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit⁴
The trustees have complied with their duty to have due regard to the commission's public benefit guidance

Achievements and Performance

Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole⁵
<ol style="list-style-type: none">1. <u>Enhancing the database of cancer research</u> In 2023-24, 7701 new projects were uploaded to the database and updates processed for 25731 projects. A server migration was completed to expand database capacity to enable further uploads. An additional 34,000 projects were coded and prepared for upload in April-May 2024 to enable production of reports on research activity in childhood cancer and survivorship during the

¹ Report includes some research activities of the group from 1 April 2023 – 4 September 2023 (e.g. publications).

² SORP reference Para 1.17

³ SORP reference Para 1.17 and 1.19

⁴ SORP reference Para 1.18

⁵ SORP reference Para 1.20

next reporting period. Enhancements were also made to the database search on the website to improve the user experience.

2. **Publications, evaluations and analysis**

- a. **Sub-Saharan Africa:** ICRP worked in partnership with the Coalition for Implementation Research In Global Oncology, clinicians and researchers in Sub-Saharan Africa on a [publication](#) in the Journal of Global Oncology (June 2023), highlighting the requirement for a research strategy for research funders focussed on local priorities, evolving cancer incidence and patient priorities.
- b. **Cancer research funding data to drive collaboration and inform action:** ICRP contributed to this [paper](#) on overcoming barriers to the collation of comprehensive global cancer research funding data is necessary to encourage international collaboration, avoid duplication, identify funding gaps, define priorities, and drive policies and programmes.
- c. **Metastatic Breast Cancer:** working with the Metastatic Breast Cancer Alliance (MBCA), ICRP updated a 2000-2013 report of investment in metastatic breast cancer (MBC) research with data from 2014-2020. The report identified that previously (2000-2013), 7% of the \$15 billion in breast cancer research dollars globally was for MBC. In 2014-2020, 13% of all breast cancer research dollars was devoted to MBC. Therefore, investment in MBC as a percentage of breast cancer research nearly doubled for grants funded in 2014-2020 compared to 2000-2013 and rose 25% above the rate of inflation. Importantly, this new analysis was guided by the priorities of people living with MBC. MBCA members living with the disease were surveyed about their research priorities. Research activity in the highest patient priority area “How can treatment resistance in each subtype be overcome?” was analysed. The percent of global MBC research dedicated to resistance increased from 15% (\$36.6 million) in 2014 to 26% (\$89.1 million) in 2020. Initial results were presented at the San Antonio Breast Cancer Symposium in December 2023. A [summary](#) has also been published.

3. **Membership and communications**

Quarterly newsletters were published via the website and distributed by email to potential new partners. Funding opportunities from partner organisations were highlighted on the [ICRP website](#) and by Twitter/X to attract global applicants. The Irish Cancer Society was welcomed to the partnership and discussions were held with the European Commission on including funded projects that had been coded to research and cancer type as part of the Lancet Commission roadmap for cancer research in Europe in 2022 in the ICRP database. Coding training sessions were held for two partner organisations during the year.

4. **Patient engagement**

Since setting up patient/advocate engagement [workshops](#) in 2021, ICRP has ensured that patient priority areas for research are an integral part of analyses and publications.

5. **Annual and virtual meetings**

Due to ongoing travel restrictions post-COVID and the challenge of finding an appropriate time for a meeting, it was decided to postpone the annual meeting until 2024. Virtual partner meetings were held monthly (with the exception of August and December) with presentations from partners on topics of interest or collaborative funding opportunities.

6. **Organisation, finance & operations**

During this period activity focused on registering the ICRP as a CIO in the UK (England & Wales) and appointing additional trustees as requested by the Charity Commission. The process of migrating financial functions to a UK bank was initiated.

Financial Review

Review of the charity's financial position at the end of the period	Para 1.21	See Fiscal Statement (Attachment IV)
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	6 month operational reserve for winding up operations
Amount of reserves held	Para 1.22	£80K (\$100K USD)
Reasons for holding zero reserves	Para 1.22	n/a
Details of fund materially in deficit	Para 1.24	n/a
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	n/a

Additional information (optional)

The charity's principal sources of funds (including any fundraising) SORP Para 1.47	Membership dues
--	-----------------

Structure, Governance and Management

Description of charity's trusts:		
Type of governing document	Para 1.25	Association Model Constitution
How is the charity constituted?	Para 1.25	Charitable Incorporated Organisation
Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees	Para 1.25	Skills audit

Reference and Administrative details

Charity name	International Cancer Research Partnership
Other name the charity uses	n/a
Registered charity number	1204566
Charity's principal address	International House, 10 Churchill Way, Cardiff, CF10 2HE, UK

Names of the charity trustees who manage the charity

Trustee Name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
Iain Frame			
Kimberly Badovinac			
Katherine McKenzie			
Lynn Turner			
Richard Stephens			
Sarah McDonald		Appointed Dec. 2023	

Report agreed at the Annual General Meeting (13 May 2024)

Financial report

The report relates to 50% of the financial year April 2023 to March 2024, as ICRP was constituted as a CIO on 4 September 2023. The fiscal year report (attached) was prepared and audited by the Canadian Partnership Against Cancer, ICRP's fiscal sponsor. For historical reasons, the account was held in USD. Work is underway to transfer residual funds and banking to the UK for the next financial reporting year 1 April 2024 – 31 March 2025, for reporting in GBP.

Summary


Income	USD	GBP⁶	Income 04 Sept 2023 – 31 March 2024 (GBP)
Balance of funds minus foreign exchange losses	121,294	96,811	48,405
Membership fees	58,500	46,692	23,346
Total			71,751

Expenditure	USD	GBP	Income 04 Sept 2023 – 31 March 2024 (GBP)
Consulting fee, legal & publication costs	52,516	41,916	20,958
Membership fees	5,805	4,633	2,317
Total			23,274

⁶ USD-GBP conversion using average annual exchange rate (https://www.trade-tariff.service.gov.uk/exchange_rates/view/2024-3?type=average)

International Cancer Research Partners (ICRP)
FINANCIAL REPORT for the period of April 1, 2023 - March 31, 2024



Chair, Finance Committee Kimberly Badovinac	Sponsor ICRP	As at March 31, 2024
Host Institution Canadian Partnership against Cancer		
SOURCES OF FUNDS	USD	USD(\$)
Balance of funds as of April 1, 2023	\$ 202,281.00	
Membership Fees for FY22/23 received in FY23/24	31,500.00	
Membership Fees for FY23/24	27,000.00	
Total funds available for April 1, 2023 - March 31, 2024	A \$	260,781.00
EXPENDITURES INCURRED		
1) Salary and Benefits		
a) Consulting Fee	\$ 52,516.11	
	Subtotal	\$ 52,516.11
2) Operations		
a) ICRP webex & other subscriptions etc.	\$ 5,804.99	
	Subtotal	\$ 5,804.99
Total expenditures incurred Apr 1, 2023 - Mar 31, 2024	B \$	58,321.10
UNSPENT BALANCE	A-B	\$ 202,459.90
TOTAL BALANCE USD		\$ 202,459.90
Unrealized foreign exchange losses (Note 2)		\$ (80,986.78)
Total Adjusted Balance USD (Note 1)		\$ 121,473.12
SIGNATURE		
<p>Note 1: As at March 31, 2024, the USD equivalent of the \$164,597.72 CAD balance in CPAC's account is \$121,473.12 USD using an exchange rate of 0.7380. This difference is due to the effect of accumulated currency fluctuation since August 1, 2013, the unrealized foreign exchange losses are \$80,986.78 USD.</p> <p>Note 2: FY23/24 membership fee of USD 8,000 from Japan Agency for Medical Research and Development was received on April 4, 2024 and will be reflected in FY24/25 statement.</p>		
<p>I hereby certify that the funds received and the expenditures incurred were transacted wholly on behalf of the grantee, and that the supporting documents are available for monitoring purposes.</p> 		
<p>Jessie Yin, CPA ,CGA Controller, Finance & Administration Canadian Partnership against Cancer May 1, 2024 Date</p>		